Home Tags Glioblastoma

Tag: Glioblastoma

Depatuxizumab Mafodotin Did Not Demonstrate Survival Benefit in INTELLANCE-1 Study

Depatuxizumab mafodotin (also known as Depatux-M, and previously known as ABT-414), an antibody-drug conjugate (ADC) being developed by AbbVie, did not demonstrate a survival...

In the War Against Brain Cancer, Accelerated Clinical Trials Are a...

More than 1.4 million people live with malignant brain tumors. Glioblastoma – the cancer that killed Senators John McCain and Ted Kennedy – is...

Study Demonstrates that Targeting EphA3 Expressing Tumor Stem Cells and Neovasculature...

The Eph type-A receptor 3 (also known as EphA3 receptor) is recognized as a functional tumor-specific therapeutic target in glioblastoma (GBM) and is significantly...
Featured Image: Nyhavn, Copenhagen, Denmark. Courtesy: © Fotolia. Used with permission.

University of Copenhagen’s Spin-out company ADCendo to Explore and Commercialize Novel...

Earlier this year spin-out company ADCendo, the University of Copenhagen and the Capital Region of Denmark entered into a worldwide license agreement to develop...

Rare Pediatric Disease Designation for ABT-414 for the Treatment of a...

The U.S. Food and Drug Administration (FDA) has a granted Rare Pediatric Disease Designation for AbbVie's ABT-414, an investigational antibody-drug conjugate (ADC) targeting the...

ASCO 2016 Emphasizes Collective Wisdom: The Future of Patient-Centered Care and...

Only a few weeks until the start of the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). This year’s ASCO, taking...

Randomized Phase I Trial Results of ABT-414 In Patients with Glioblastoma...

Updated interim results from a Phase I clinical trial of ABT-414 (AbbVie) in patients with glioblastoma multiforme (GBM), an aggressive form of brain cancer,...

Collagen-VI-Alpha-1 is a New Target and a Marker of Poor Outcome...

Functional targeted therapy has unfortunately failed to improve the outcome of glioblastoma patients. While success stories evidenced by the use of antibody-drug conjugates or...
ESMO 2014 Congress - Madrid, Spain

Initial Phase I Trial Results of anti-EGFR drug ABT-414 in the...

With a median survival between 1 and 2 years and no long-term curative treatments, the management of patients with Glioblastoma Multiforme (GBM), the most common and most aggressive type of malignant primary brain tumor, remains challenging.
FDA_EMA

Phase I Trial Results in GBM Lead to Orphan Drug Designation...

The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designation to AbbVie's investigational compound ABT-414, an anti-epidermal growth factor receptor antibody drug conjugate, which is being evaluated for safety and efficacy in patients with glioblastoma multiform.

FEATURED RESOURCES